As 2025 comes to a close, it is clear that this has been a defining year for Glooko and for the broader evolution of diabetes care. Following the close of our Series F, we entered the year with a clear focus: deliver on our strategy, expand our global impact, and continue building technology that helps make diabetes care more connected, actionable, and human.

Accelerating our Mission through Strategic Leadership and a Connected Care Continuum

Over the past year, we reached several important milestones in support of that goal. We expanded our capabilities through the acquisition of Monarch Medical Technologies and its EndoTool Glucose Management System, bringing together complementary capabilities across outpatient and inpatient diabetes and glycemic management.

We strengthened our ecosystem with the launch of our Abbott FreeStyle Libre integration in the U.S., helping ensure that critical glucose data can flow more seamlessly to people with diabetes and their care teams.

We also reinforced our clinical leadership with the appointment of Mark Clements, M.D., Ph.D., as Chief Medical and Strategy Officer, underscoring our commitment to evidence-based innovation and strong clinical partnership.

Driving Digital Health Adoption in EMEA

We also saw meaningful traction across geographies and care settings.

In EMEA, we continued to expand our presence as health systems look for scalable, interoperable digital solutions to support diabetes care. At the same time, Glooko XT, our remote monitoring solution available only in France, introduced new features and strengthened its gestational diabetes management capability, an area where timely insights and coordinated care are critical for both maternal and fetal outcomes. These areas of momentum reflect the growing demand for digital tools that can support diverse patient populations and clinical workflows.

Further Enhancing our Diabetes Management Platform to Improve Care

On the product front, we continued to invest in tools designed for the realities of care delivery.

The launch of the new Glooko clinic dashboard marked an important step forward in helping clinics and health systems move beyond raw data to clearer insights, enabling more informed, timely decisions at the point of care. Across the organization, we remained focused on bringing teams together around a shared mission and shared standards, ensuring that our growth continues to be purposeful and aligned.

A reality faced by care teams each day is the need for timely, actionable data within existing clinical workflows. That’s why we invested further into our EHR capabilities this year and joined the Epic Showroom to make it easier for hospitals and health systems to seamlessly integrate their EHR with Glooko, helping reduce clinician burnout and optimize clinical workflows.

The Glooko Mobile App for people with diabetes also continued to innovate in 2025 with a redesigned food tracker for more insightful nutrition data and insights, revised insulin cards for more clarity, and viewable GLP-1 doses. These enhancements enable care teams to make more informed and timely treatment decisions between appointments using their patients’ health data – all viewable in one place.

How the U.S. Healthcare System is Moving Toward Data-Driven, Accountable Diabetes Care

These milestones matter, but they are occurring against a broader backdrop of change in healthcare that strongly validates this direction. The latest American Diabetes Association’s Standards of Care reinforce what clinicians and people with diabetes have long understood: technology-enabled management and data-driven insights are now foundational to delivering high-quality diabetes care.

At the same time, policy initiatives such as the CMS ACCESS program signal a growing emphasis on interoperability, data liquidity, and the responsible use of health data to improve outcomes at scale.

Together, these shifts point to a future in which diabetes care is increasingly proactive rather than reactive, and where data is not simply collected, but translated into meaningful action.

Regulatory momentum is reinforcing the importance of consistent, evidence-based glycemic management across care settings. CMS’s upcoming electronic clinical quality measure (eCQM) requirements for inpatient glycemic management, expected to take effect in 2026, reflect a growing emphasis on standardization, measurement, and accountability in hospital-based diabetes care. Solutions like EndoTool are at the forefront of this shift, helping health systems operationalize best practices, support clinical decision-making, and drive more reliable glycemic outcomes at scale.

For healthcare providers and care teams, this evolution brings both opportunity and urgency. As care becomes more continuous and data-rich, success depends on having tools, like Glooko’s EHR integrations, that reduce complexity, surface what matters most, and fit naturally into clinical workflows. The goal is not more data for its own sake, but clearer insight that supports better decisions and more personalized care.

For health systems, the focus is expanding to population-level impact. Managing chronic disease across diverse populations requires platforms that enable earlier intervention, more consistent care, and coordination across settings. Interoperable digital solutions, like Glooko, are becoming essential infrastructure for balancing quality, efficiency, and cost in an increasingly complex care environment.

Leveraging Scalable Healthcare Technology to Deliver Consistent Diabetes Care Around the World

Globally, the stakes are even higher. Diabetes prevalence continues to rise across regions with very different healthcare resources and delivery models. Scalable digital health solutions offer a path to extend evidence-based care, support clinicians, and bring greater consistency to diabetes management worldwide. As global standards and policies evolve, technology will play a central role in enabling more equitable access to high-quality care.

The Road Ahead for Glooko

Looking ahead, our focus at Glooko remains clear. We will continue investing in platforms that turn diabetes data into insight, insight into action, and action into better outcomes. We will deepen partnerships across the ecosystem and stay closely aligned with clinicians, health systems, and people with diabetes as their needs continue to evolve.

2025 was a year of momentum for Glooko. More importantly, it reinforced why our mission matters. As the future of diabetes care continues to take shape, we are energized by the opportunity to help lead the way.

EndoTool is developed and marketed by Monarch Medical Technologies, a Glooko Company. EndoTool is an FDA-cleared Class II medical device indicated for inpatient use as described in its Instructions for Use. Glooko’s diabetes management platform and EndoTool are currently independent solutions.

We are proud to share that Glooko has been recognized by The Healthcare Technology Report as one of the Top 50 Healthcare Technology Companies of 2025. This honor reflects the progress we are making toward building a more connected, personalized, and accessible future for people with diabetes and the clinicians who support them.

Each year, this list highlights organizations that are shaping the trajectory of healthcare through innovation and meaningful impact. For Glooko, this recognition reinforces the work taking place across our teams to simplify the complexity of diabetes care. Whether it is bringing data from devices into a single platform, supporting timely clinical decision making, or expanding digital tools that help people manage their diabetes with confidence, our mission has remained constant. We aim to improve patient outcomes through connected care platforms that work in the real world.

This award also reflects how far we have come in strengthening our portfolio. From the continued evolution of the Glooko platform, to the future integration of the inpatient insulin dosing technology of EndoTool, developed by Monarch Medical Technologies, a Glooko Company, to our partnerships that expand clinical value and accessibility, we are building an innovative approach to diabetes management that spans the full care journey. These advancements are the direct result of our teams’ expertise and commitment to the people who rely on our products every day.

Most importantly, this recognition is a reminder of why we do this work. Behind every data point is a person managing a lifelong condition while balancing the demands of life, family, and care. Our responsibility is to meet them where they are with tools that are intuitive, reliable, and informed by real clinical needs.

We are honored to be included among so many forward-thinking healthcare technology leaders. As we look to 2026, we remain focused on delivering solutions that empower clinicians, support health systems, and make life better for people with diabetes around the world.

EndoTool is developed and marketed by Monarch Medical Technologies, a Glooko Company. EndoTool is an FDA-cleared Class II medical device indicated for inpatient use as described in its Instructions for Use. Glooko’s diabetes management platform and EndoTool are currently independent solutions.

October is Cybersecurity Awareness Month, but for Glooko, the only diabetes management company with multiple industry-leading security certifications, our commitment to protecting patient health data is a year-round mission.

According to Glooko CEO Mike Alvarez, one of our diabetes management company’s core differentiators is our commitment to patient safety and data privacy, which enables us to build and maintain trust with hospitals, health systems, clinics, and people living with diabetes.

As the healthcare industry faces rising cyberattacks, Glooko understands that securing health data and ensuring the security and privacy of this sensitive information is not just a policy — it’s a core responsibility.

Building a Foundation of Trust Through Security Certifications

Security isn’t a single feature you can switch on; it’s a comprehensive framework built on continuous commitment, sophisticated technology, and rigorous auditing.

As the most secure diabetes management platform, Glooko has invested heavily in achieving and maintaining a number of rigorous global security certifications and standards, which serve as a powerful testament to the maturity and diligence of our security practices that safeguard the sensitive personal and health data of our users with diabetes.

Here are the key standards and certifications that build Glooko’s security backbone:

• ISO 27001: This globally recognized information security management standard outlines requirements for an information security management system (ISMS). Achieving this certification means an organization has a systematic approach to managing sensitive company and customer information.
• SOC 2 Type II and SOC 3 Certification: These internationally recognized global reporting standards, validated by an auditing firm, verify that Glooko’s controls across its employees, systems, and processes fully secure all customer data, software, and company assets.
• HITRUST Risk-based, 2-year (r2) Certification: Achieving this healthcare industry gold standard confirms our stringent, independently-audited security controls meet the highest requirements of frameworks like HIPAA and NIST. This places us in an elite group dedicated to protecting sensitive patient health data. Explore our recent study on strengthening our cyber resilience…
• HIPAA Compliance: This U.S. federal law ensures the protection of sensitive patient health information from being disclosed without the patient’s consent or knowledge.
• The NHS Digital Data Security and Protection Toolkit (DSPT): For operations in the U.K., this framework ensures that patient data is handled securely and in a way that respects privacy.
• GDPR: This comprehensive European Union law gives individuals control over their personal data by setting strict rules for how organizations worldwide must collect, process, and protect that information.

How Diabetes Patient Health Data is Protected on a Day-to-Day Basis

Beyond the certifications, hundreds of controls are implemented to ensure data remains secure at Glooko. Our approach, covering protection, defense, response, and recovery, includes:

• Continuous Vulnerability Management: Regular penetration testing and vulnerability scans are conducted to proactively identify and address potential weaknesses in their systems.
• Internal Governance: A dedicated governance board oversees our diabetes management company’s policies, ensuring that security and privacy are considered in all decisions.
• Employee Training: A core element of any security strategy is the people. Team Glooko receives regular, mandatory training on data security and privacy protocols.
• Privileged Access Management: Policies are in place to ensure that only authorized personnel have access to sensitive information.
• Secure Software Development Lifestyle (SSDLC): Security code reviews, threat modeling, and static and dynamic code scans are completed during the software development lifecycle

Your Data, Your Control

A crucial part of data privacy is the user’s right to control their information. We make it clear that personally identifiable data is never shared without explicit consent. When using the platform through a healthcare provider, Glooko functions as a part of the healthcare provider’s operations, always adhering to the same stringent privacy standards.

Our Constant Commitment to Protecting Patient Safety

Cybersecurity Awareness Month is a great starting point, but data protection requires constant, evolving, and year-round efforts because threats are always changing.

Through a combination of robust technical controls, a culture of security, and adherence to global standards, Glooko’s commitment to trust and privacy is a fundamental part of our connected care company beyond October.

When healthcare professionals manage a large population of patients with diabetes, they often lack a clear, organized, and comprehensive view of patients’ pertinent health data.

To help address this challenge, we designed the new clinic dashboard in the Glooko diabetes management platform. Available in select countries, the dashboard helps healthcare providers, including primary care providers, endocrinologists, and nurses, at hospitals, health systems, and clinics streamline their diabetes population health management.

Developed for busy healthcare professionals, the new Glooko clinic dashboard is based on TIDE (Timely Interventions for Diabetes Excellence) metrics to help address the challenge of managing a large diabetes patient population. This user-friendly view provides at-a-glance insights into patient population trends and key clinic metrics, making it easier for the entire care team to interpret complex data and guide more efficient decision-making and clinic strategy.

Built on TIDE Metrics for Smarter Diabetes Care

Leveraging evidence-based risk identification logic developed by Stanford researchers to further enhance clinical insights, personalize care, and demonstrate scalable, cost-effective outcomes, the TIDE dashboard, which demonstrated in a 2022 study to reduce screen time for healthcare providers reviewing patient data by 86%, is a powerful tool designed to help clinical teams manage large populations of patients with type 1 diabetes.

The TIDE dashboard uses smart algorithms to analyze and remotely monitor data from continuous glucose monitoring (CGM) devices, helping care teams efficiently and effectively manage their patients’ health. Using essential glucose measures like Time in Range and hypoglycemia, the TIDE model also prioritizes which patients need immediate attention by sorting them by clinical risk, so healthcare providers can focus on those who need it most without sifting through every patient’s data individually.

The TIDE model-based Glooko clinic dashboard offers our professional users a user-friendly way to tackle the challenge of managing a large patient population with three intuitive sections.

Understand Patient Population At-A-Glance

The Population Metrics section of the new Glooko clinic dashboard helps care teams understand the overall health and engagement of their clinic’s patient population in a centralized and concise view. This space displays the total number of patients with diabetes, identifies who is actively monitoring their blood glucose by blood glucose monitors (BGM) or CGM, and shows which patients have completed their Glooko account registration and are actively syncing their health data remotely with our connected care platform.

By centralizing these metrics, this comprehensive section of the dashboard helps healthcare providers shape clinic strategy more efficiently and better understand which patients to contact to activate their Glooko account to make more informed decisions based on synced health data.

Prioritize Care Based on Key CGM Metrics

The CGM Patient Risk Stratification section of the new Glooko clinic dashboard helps healthcare providers prioritize patient care and gives care teams a streamlined view of their patient population, sorted by clinical risk based on key glucose metrics from CGMs. Care teams can easily spot which patients need attention first. The dashboard ranks patients using indicators like Time in Range, Time Below Range, and other key CGM indicators, so healthcare providers can prioritize outreach and interventions based on the most important CGM data, making it easier for them to focus their time on the patients who need it most.

Boost Patient Engagement and Optimize Care

The Engagement Metrics module of the new Glooko clinic dashboard helps healthcare providers spot engagement gaps in their patient population over the past 90 days.

The Patient Account Status section examines the patient population to see if they’ve set-up their Glooko account based on Activated, Invited Pending, Never Invited, and Likely Duplicates. With these key metrics, care teams can quickly see which patients with diabetes haven’t completed the sync to Glooko with their diabetes and health monitoring devices as well as the activation process, allowing for more efficient follow-up and activation.

In the Sync Methods section, care teams can see how patients with diabetes are syncing their data with Glooko. When more health data is synced with Glooko from the cloud, Glooko Mobile App, Transmitter, or Uploader, care teams can make more informed and timely treatment decisions.

Experience Glooko’s New Clinic Dashboard

Ready to see how the intuitive, new Glooko clinic dashboard can optimize diabetes population health management at your clinic, hospital, or health system? Contact our team for a demo.

Today marks an important milestone in our mission to transform diabetes care. I am excited to share that Glooko has acquired Monarch Medical Technologies, creators of the EndoTool® Glucose Management System.

With this acquisition, Glooko is positioned to become the only diabetes management company with the potential to connect the full continuum of care — from home to hospital and back again. By bringing together EndoTool’s proven inpatient insulin dosing technology with Glooko’s leading outpatient platform, we aim to create a future where care is seamless, safer, and more supportive for both people living with diabetes and healthcare providers.

For patients, this means fewer disruptions as they move between settings, reduced risk of dangerous glycemic events, and more confidence that their care is connected. For healthcare providers, it means access to tools that simplify complex insulin management, standardize protocols, and free up time to focus on what matters most, which is caring for people.

This step also sets the foundation for Glooko’s future: using data and AI to help clinicians anticipate risks earlier, personalize care at scale, and improve outcomes under value-based models. By aligning advanced technology with clinical guidelines and EHR workflows, we can help hospitals and health systems deliver higher-quality care while lowering costs.

Our mission has always been clear: to simplify diabetes management, strengthen connections across the care team, and improve lives. This acquisition represents an important stride toward that vision.

Together, we are building a future where diabetes care is more connected, proactive, and patient-centered than ever.

EndoTool is developed and marketed by Monarch Medical Technologies, a Glooko Company. EndoTool is an FDA-cleared Class II medical device indicated for inpatient use as described in its Instructions for Use. Glooko’s diabetes management platform and EndoTool are currently independent solutions.

The Glooko 2025 Global Diabetes Report offers a comprehensive look at how real-world data can drive better outcomes in diabetes care. Powered by billions of data points across 30+ countries, this report uncovers meaningful trends in glycemic management, technology adoption, and behaviors among people living with Type 1, Type 2, and gestational diabetes.

From the rise of remote monitoring to the impact of advanced technologies like Continuous Glucose Monitors (CGMs) and Automated Insulin Delivery (AID) systems, this report explores how personalized insights can be used to better inform personalized care, predict risk, and guide clinical decision-making.

Whether you’re a clinician, researcher, or innovator in diabetes management technology, this report highlights how data can be turned into action — helping to shape a smarter, more connected future of diabetes management.

Download the report

At Glooko, we are committed to simplifying diabetes insights and management for people living with diabetes and healthcare providers alike. That’s why our platform is compatible with more than 200 diabetes and health monitoring devices and growing.

As a company, we could not be more pleased to share that we recently expanded our capabilities to integrate with Abbott’s FreeStyle Libre CGMs in the United States. This integration brings glucose data to more clinics and health systems in our all-in-one solution for diabetes management.

This milestone is more than just a technological advancement — it’s about empowering people with Type 1, Type 2, and gestational diabetes, as well as prediabetes, to become active owners in their health. By combining the precision of Abbott’s FreeStyle Libre CGMs with Glooko’s comprehensive platform, we can provide people living with diabetes and their care teams, including endocrinologists and nurses, with a unified, holistic view of diabetes management and irrefutable information.

From glucose trends to lifestyle behaviors like diet and physical activity, this latest integration ensures that critical insights are easily accessible when and where they are needed most. For healthcare providers and health systems, this means the ability to seamlessly access and analyze patients’ CGM data through Glooko and established electronic health record (EHR) solutions, more informed decision-making, and improved patient outcomes. For people living with diabetes, it means greater confidence in their care and health.

As the number of people with diabetes continues to grow, the need for seamless, data-driven solutions has never been greater. Our new integration with Abbott’s FreeStyle Libre CGMs represents a significant step forward in delivering better, more connected care. This partnership is sure to have a positive impact on the millions of people who rely on FreeStyle Libre CGMs and Glooko.

In the United Kingdom, diabetes technology has rapidly advanced over the past two decades, with platforms like Glooko playing a central role in simplifying care and management.

In honor of Diabetes Week U.K. (9 June to 15), we’re taking a look at the state of diabetes, technology designed to better manage the condition, and the outlook on the evolution of diabetes care and technology.

The State of Diabetes in the United Kingdom

Diabetes is a significant public health concern in the U.K. According to Diabetes U.K., more than 5.8 million people are currently living with the condition. Of these, approximately 4.6 million have been diagnosed and an estimated 1.3 million people may be living with undiagnosed Type 2 diabetes.

Of those diagnosed with diabetes in the U.K., Type 2 diabetes accounts for approximately 90% of cases. While risk factors for Type 1 diabetes include family history and the presence of other autoimmune conditions, Type 2 diabetes risk is heightened obesity, family history, a history of gestational diabetes, specific medications, and other factors.

To address the growing prevalence of diabetes and support those affected, the National Health Service (NHS) offers various education programs aimed at empowering individuals with the knowledge and skills necessary to manage their diabetes effectively, improve health outcomes, and reduce the risk of complications.

For individuals with Type 2 diabetes, programs like DESMOND (Diabetes Education and Self-Management for Ongoing and Newly Diagnosed) and the X-PERT Diabetes Programme provide education on managing the condition through lifestyle changes and self-monitoring. For those with Type 1 diabetes, the DAFNE (Dose Adjustment For Normal Eating) program offers guidance on insulin management and dietary considerations and Digibete helps young people, families, and communities better manage Type 1 diabetes. Additionally, the VICTOR program is designed for adults with Type 2 diabetes who are on insulin therapy and focuses on adjusting insulin doses in response to routine changes.

Diabetes Technology Today

In the U.K., diabetes technology is advancing quickly with Glooko helping streamline data management across compatible diabetes and health monitoring devices, including:

• Hybrid closed loop (HCL) systems, which combine continuous glucose monitoring (CGM) with insulin pumps to automatically adjust insulin delivery based on real-time data.
• Devices like Tandem t:slim X2 require cable downloads, while mylife Loop powered by CamAPS® FX and Omnipod® 5 use cloud-to-cloud integration.
• CGMs provide glucose trends and alerts and are often compatible with pumps and cloud platforms.
• Abbott FreeStyle Libre CGMs data can be seen within Glooko through the upload of data from HCL-compatible insulin pumps.
• Fitness and health monitoring apps can track steps, weight, and blood pressure.
• Smart pens and connected pens allow for remote or in-clinic dose tracking.

Transforming Diabetes Care in the United Kingdom with Glooko

Across the country, more than 85,000 people living with diabetes use Glooko’s digital health platform to manage their diabetes and more than 500 clinics are using Glooko to provide better care to their patients.*

Through our data*, we identified key metrics for time in range for people with Type 1, Type 2, and gestational diabetes in the U.K. using Glooko during 2024.

Today, there is an increased interest in TITR and TIR as a result of the recent technology available for managing diabetes. The Glooko diabetes data management platform helps healthcare providers monitor TIR and TITR to improve glycemic outcomes for people living with diabetes, bringing data from multiple devices into one platform with comprehensive charts and graphs. It ensures consistent data access — even without connected devices — and meets high standards for data protection, including GDPR compliance, to support safe, effective, and standardised diabetes care.

The Future of Diabetes Care in the United Kingdom

The future of diabetes care in the U.K. lies in advancing technology and deeper collaboration. Recent key developments include moving towards fully closed loop systems, integrating AI-enabled personalized insights, and aligning diabetes management with weight loss medications. Continued innovation will help provide more tailored, effective treatment options for people living with diabetes.

Progress also depends on strong partnerships with leading diabetes organisations like the Diabetes Technology Network (DTN-UK) and Diabetes National Networking Forums (NNF).

The future of diabetes care in the U.K. lies in advancing technology and deeper collaboration. Recent key developments include moving towards fully closed loop systems, integrating AI-enabled personalized insights, and aligning diabetes management with weight loss medications. Continued innovation will help provide more tailored, effective treatment options for people living with diabetes.

By showcasing technologies such as hybrid closed loop systems at local events from these leading organisations and through initiatives like our Academy program, a collaboration between Glooko and the Association of British Clinical Diabetologists(ABCD)/DTN-UK providing free education for medical professionals in the U.K., we help educate, support, and empower both clinicians and people living with diabetes across the country.

*Internal Glooko data; based on active Glooko users that synced during 2024

At Glooko, we empower healthcare providers with the tools and insights they need to make informed decisions quickly and easily to improve the health outcomes of their patients living with diabetes.

With nearly half of physicians reporting at least one burnout symptom in a recent study from the American Medical Association, it’s critical we make diabetes data management simpler to not overburden those providing care.

That’s why the Glooko platform integrates with leading electronic health record (EHR) systems in the U.S., including Epic, Oracle Health, MEDITECH, Greenway Health, eClinicalWorks, NextGen, and Athenahealth, making our diabetes management platform seamlessly and securely available within this critical healthcare technology and eliminating the need to platform switch.

Why EHR Integrations Matter

Diabetes care is complex, and healthcare providers face the challenge of managing patient data across multiple systems. In an era where time is precious and clinicians are already spending much of their time on administrative tasks, clinicians need timely access to the most relevant health data without the inefficiencies of navigating multiple data platforms.

By integrating Glooko into EHRs, we streamline how healthcare providers access diabetes data, enabling them to provide the highest quality care. Our integrations provide clinicians and care teams with immediate access to comprehensive data from more than 200 diabetes and health monitoring devices used by their patients, eliminating the need for additional logins and manual data entry by people living with diabetes each day.

EHR integrations not only optimize existing systems, but they also have the potential to enhance clinical decision-making by giving clinicians the full picture of a person’s health. It empowers them to make faster, more informed treatment decisions. That’s why health systems spend $2.5 million to $1.2 billion on EHR integrations each year. They’re powerful and their care teams can reap the benefits of reduced documentation burden.

How It Works

By leveraging SMART on FHIR technology and HL7, standard interoperability frameworks, Glooko integrates with existing EHR systems at hospitals and health systems. Healthcare providers can then access patients’ timely glucose data, medication logs, activity levels, food intake, and much more without leaving the EHR.

The integrations support healthcare systems by offering a single, unified view of a person’s diabetes information, all while ensuring secure, HIPAA-compliant data exchange. The technology is designed to streamline workflows, making it easier for clinicians to focus on what truly matters: providing quality care for their patients.

A Step Toward the Future of Diabetes Care

Following the COVID-19 pandemic, clinical teams who provide care to the more than 38 million people in the U.S. living with diabetes have greatly declined in number, furthering the urgent need for seamless, data-driven solutions to help reduce administrative burdens and workloads that drive burnout.

• Since 2022, more than 138,000 nurses left the workforce due to stress, burnout, and retirement. New data from the NCSBN reveals almost 40% of nurses intend to leave the workforce by 2029, leaving the remaining time-pressed nurses to provide care to an already large patient population.
• Based on a recent GoodRx study, more than 70% of U.S. counties don’t have an endocrinologist and the number of trained endocrinologists is declining, meaning primary care providers must be knowledgeable in diabetes management and shoulder the workload.
• There is a significant shortfall of certified diabetes care and education specialists (CDCES), impacting diabetes care quality. In the U.S., there are about 19,500 diabetes educators — roughly 1 CDCES per 1,000 individuals with diabetes. An additional 35,000 educators would be required to meet the current demands of patients in the U.S. alone, furthering the workload burden.

And the burnout by clinicians and care teams is only going to grow greater as 98 million American adults have prediabetes, according to the CDC.

By optimizing and integrating with leading EHR systems, Glooko is taking a significant step forward in transforming diabetes management and reducing extra steps taken by healthcare providers to improve the quality of care. Our integrations help improve workflows, limit platform switching, simplify clinical decision-making, and support better outcomes for both healthcare providers and people with diabetes.

These integrations represent our ongoing commitment to delivering cutting-edge, interoperable solutions that empower both clinical teams and patients in making diabetes easier to manage.

Ready to Learn More?

Healthcare providers and hospital systems can access EHR integrations by reaching out to our dedicated team for a demo. With robust support from our dedicated team, some integrations, like with Epic, can be up and running within a weeks, making it easier than ever to take advantage of the benefits Glooko has to offer.

To learn more about Glooko’s many EHR integrations, visit our Integration Portal.

Over the past several months since stepping into the role of CEO at Glooko, I’ve been reflecting on the incredible progress we’ve made, and the immense opportunities that lie ahead. Each day has reaffirmed my belief that our mission to transform diabetes care is both urgent and achievable. I’m more energized than ever to guide Glooko toward a future where we deliver an even greater impact for people with diabetes and those who care for them.

When I think about the future of diabetes care, one word comes to mind: transformation. Across the globe, health systems, clinicians, and people living with diabetes are looking for a holistic approach, one that brings together cutting-edge technology, patient-centric insights, and secure, scalable solutions. At Glooko, we’ve made it our mission to deliver exactly that.

Our Vision: Transforming Diabetes Care

We believe in transforming diabetes care by making it simpler, more connected, and fundamentally centered on people with diabetes. This vision underpins every decision we make, whether we’re enhancing our platform’s EHR integration, partnering with global device manufacturers, or expanding our footprint in new markets.

Our Mission: Simplifying Care and Strengthening Connections

At Glooko, we say: “We simplify care, strengthen connections, and together create a brighter future for people living with diabetes, healthcare providers, and caregivers.”

Simplify Care

We hear time and again about fragmented workflows and siloed data, forcing providers and patients to juggle multiple device platforms (mobile and web), apps, and logins. Our platform intends to change this, meaning clinicians can potentially spend less time on administrative tasks and more time where they’re needed most: caring for patients and focused on improving outcomes.

Strengthen Connections

We also see the power of community and shared decision-making. Through Glooko, patients, caregivers, and healthcare teams can collaborate more effectively, share real-time data, and gain insights that drive meaningful change in care plans. We aim to reduce the cognitive burden of diabetes data and decision making.

In my view, these are the five biggest differentiators that make Glooko stand out:

1. Patient First Mindset: Everything we do revolves around putting patients first. We collaborate closely with clinicians, caregivers, and people living with diabetes to ensure our technology meets real-world needs.
2. Commitment to Quality and Security: From ISO 27001 to HiTrust and SOC 2 Type 2 certifications, our platform is backed by enterprise-grade security and rigorously tested reliability. We understand that healthcare data is precious and that trust is earned through quality.
3. Innovation That Matters: Our platform is more than a “data upload tool.” It’s an engine designed to support clinical decision making. Whether it’s EHR interoperability or automated patient nudges, we constantly push boundaries to develop meaningful solutions that scale globally.
4. High-Performance Culture: Within the company, we’re building a talented, global team that challenges the status quo. This energy fuels our drive to expand into new markets, partner with industry leaders, and improve access to diabetes care around the world.
5. Better Together: Collaboration is in our DNA, and that includes partnerships with device manufacturers, healthcare providers and hospital systems. By joining forces with stakeholders across the healthcare ecosystem, we have the opportunity to create value that benefits everyone, especially people living with diabetes.

Scaling for the Future

Our work has already touched millions of lives, but we’re just getting started. With rising rates of diabetes worldwide, the need for an integrated, secure, and human-centered solution has never been greater. That’s why we’re investing in global expansion, forging new alliances, and refining our platform to make sense of the high volume of data in diabetes care.

Scaling effectively also means staying true to our roots. Our commitment to patient outcomes, uncompromising quality, and secure innovation will remain the bedrock of Glooko’s growth. As we continue to expand, our North Star will always be the same: transforming diabetes care on a global scale and making diabetes easier to manage for everyone in the diabetes care ecosystem.

A Commitment to People Living with Diabetes, Above All

Behind every data point or device upload is a person managing a complex, life-altering condition. We never lose sight of that human element. As Glooko grows, our Patients First value continues to guide us toward solutions that truly make a difference, reducing clinical burdens, improving outcomes, and helping people with diabetes live fuller, healthier lives.

MKT-0532 01